Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

Stock analysts at StockNews.com initiated coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Get Free Report) in a research report issued to clients and investors on Thursday. The firm set a "hold" rating on the biopharmaceutical company's stock.

A number of other brokerages have also weighed in on RVNC. HC Wainwright restated a "neutral" rating and issued a $6.60 price objective on shares of Revance Therapeutics in a report on Friday, November 8th. Mizuho reduced their target price on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating for the company in a research report on Tuesday, December 10th. Barclays lowered their price target on shares of Revance Therapeutics from $7.00 to $3.00 and set an "equal weight" rating on the stock in a research report on Monday, December 23rd. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Revance Therapeutics in a research note on Friday, January 17th. Nine investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $8.39.

Revance Therapeutics Price Performance

Revance Therapeutics stock remained flat at $3.65 during midday trading on Thursday. Revance Therapeutics has a 1 year low of $2.30 and a 1 year high of $7.56. The stock has a 50 day moving average price of $3.39 and a 200 day moving average price of $4.57.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last released its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The firm had revenue of $59.88 million during the quarter, compared to analyst estimates of $67.73 million. On average, research analysts expect that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RVNC. Charles Schwab Investment Management Inc. increased its position in shares of Revance Therapeutics by 0.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 797,299 shares of the biopharmaceutical company's stock worth $2,424,000 after purchasing an additional 6,462 shares during the last quarter. Rhumbline Advisers boosted its stake in Revance Therapeutics by 5.1% during the fourth quarter. Rhumbline Advisers now owns 142,603 shares of the biopharmaceutical company's stock worth $434,000 after buying an additional 6,885 shares during the period. Sei Investments Co. increased its position in shares of Revance Therapeutics by 52.5% during the second quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 7,628 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Revance Therapeutics by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,161 shares of the biopharmaceutical company's stock valued at $105,000 after acquiring an additional 7,890 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Revance Therapeutics by 29.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 42,296 shares of the biopharmaceutical company's stock worth $109,000 after acquiring an additional 9,601 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.